[go: up one dir, main page]

MX2018003313A - Celulas asesinas naturales modificadas con propiedades anti-fuctacticas y sus usos. - Google Patents

Celulas asesinas naturales modificadas con propiedades anti-fuctacticas y sus usos.

Info

Publication number
MX2018003313A
MX2018003313A MX2018003313A MX2018003313A MX2018003313A MX 2018003313 A MX2018003313 A MX 2018003313A MX 2018003313 A MX2018003313 A MX 2018003313A MX 2018003313 A MX2018003313 A MX 2018003313A MX 2018003313 A MX2018003313 A MX 2018003313A
Authority
MX
Mexico
Prior art keywords
fuctactic
properties
natural killer
modified natural
killer cells
Prior art date
Application number
MX2018003313A
Other languages
English (en)
Inventor
C Poznansky Mark
Vianello Fabrizio
Original Assignee
The General Hospital Corp Dba Massacsetts General Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The General Hospital Corp Dba Massacsetts General Hospital filed Critical The General Hospital Corp Dba Massacsetts General Hospital
Publication of MX2018003313A publication Critical patent/MX2018003313A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)

Abstract

La presente invención proporciona métodos ex vivo para hacer composiciones de células asesinas naturales modificadas que tienen propiedades generales anti-fuctácticas para el tratamiento efectivo y eficiente de tumores o cánceres en un paciente y composiciones y uso de las mismas.
MX2018003313A 2015-09-18 2016-09-16 Celulas asesinas naturales modificadas con propiedades anti-fuctacticas y sus usos. MX2018003313A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562220857P 2015-09-18 2015-09-18
US201662303367P 2016-03-03 2016-03-03
US201662303364P 2016-03-03 2016-03-03
PCT/US2016/052333 WO2017049228A1 (en) 2015-09-18 2016-09-16 Modified natural killer cells having anti-fugetactic properties and uses thereof

Publications (1)

Publication Number Publication Date
MX2018003313A true MX2018003313A (es) 2018-11-09

Family

ID=57121512

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003313A MX2018003313A (es) 2015-09-18 2016-09-16 Celulas asesinas naturales modificadas con propiedades anti-fuctacticas y sus usos.

Country Status (11)

Country Link
US (1) US20170100433A1 (es)
EP (1) EP3350317A1 (es)
JP (2) JP7098518B2 (es)
CN (1) CN108368485A (es)
AU (1) AU2016324293A1 (es)
CA (1) CA2999090A1 (es)
HK (1) HK1259030A1 (es)
IL (1) IL258193A (es)
MX (1) MX2018003313A (es)
TW (1) TW201718851A (es)
WO (1) WO2017049228A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3765519B1 (en) * 2018-03-13 2024-01-17 Fundación para la Investigación Biomédica del Hospital Universitario la Paz Anti-cxcr4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0906954A1 (en) * 1997-09-29 1999-04-07 Applied Research Systems ARS Holding N.V. Amino-terminal truncated c-c chemokines as chemokine antagonist
US6171590B1 (en) * 1998-09-30 2001-01-09 Corixa Corporation Chemokine receptor peptide for inducing an immune response
US20070134657A1 (en) * 2002-12-06 2007-06-14 General Hospital Corporation, The Methods and compositions relating to gradient exposed cells
JP2008519052A (ja) 2004-11-05 2008-06-05 ザ ジェネラル ホスピタル コーポレイション 薬剤によるヒト遊走性細胞の合目的的挙動
CA2717071A1 (en) * 2008-03-20 2009-09-24 Carolus Therapeutics, Inc. Methods of treatment using anti-mif antibodies
AU2011279201B2 (en) 2010-07-13 2016-01-21 Celularity Inc. Methods of generating natural killer cells
US20140120555A1 (en) * 2011-06-20 2014-05-01 Pierre Fabre Medicament Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
CA2920377A1 (en) * 2013-08-05 2015-02-12 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy

Also Published As

Publication number Publication date
US20170100433A1 (en) 2017-04-13
EP3350317A1 (en) 2018-07-25
IL258193A (en) 2018-05-31
HK1259030A1 (zh) 2019-11-22
CN108368485A (zh) 2018-08-03
AU2016324293A1 (en) 2018-04-26
JP7098518B2 (ja) 2022-07-11
JP2022130602A (ja) 2022-09-06
CA2999090A1 (en) 2017-03-23
WO2017049228A1 (en) 2017-03-23
JP2018533915A (ja) 2018-11-22
TW201718851A (zh) 2017-06-01

Similar Documents

Publication Publication Date Title
IL268554A (en) Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
ECSP15026557A (es) Compuestos y sus métodos de empleo
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
CO2019007298A2 (es) Inhibidores de tgfβ1 isoforma-específicos contexto-permisivos y uso de los mismos
MX2018006831A (es) Metodos de tratamiento de neoplasias malignas.
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
MX2017005258A (es) Terapia combinada para tratamiento de enfermedad.
UY35427A (es) Compuestos y sus usos en la modulación de la hemoglobina
CL2015002194A1 (es) Inhbidores de erk y sus usos
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
EA201691866A1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
UY35425A (es) Compuestos y sus usos en la modulación de la hemoglobina
MX379193B (es) Composiciones en solucion solida y su uso en inflamacion cronica.
UY35426A (es) Compuestos y sus usos en la modulación de la hemoglobina
AU361329S (en) Footstool
CL2015003704A1 (es) Péptidos y peptidomiméticos en usos de combinación y tratamientos para la subpoblacion de pacientes con cáncer
HUE047540T2 (hu) Javított allogén dendritikus sejtek rák kezelésében történõ alkalmazásra
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
MX2020004837A (es) Inhibidores de la vía de adenosina para el tratamiento del cáncer.
CR20160047A (es) Inhibidores de rorc2 y sus métodos de uso
PE20151925A1 (es) Anticuerpos anti-igf-1r con abolicion de la union al fcrn y su utilizacion en el tratamiento de enfermedades oculares vasculares
MX374385B (es) Apilimod para uso en el tratamiento de melanoma.
MX2018013409A (es) Métodos y dispositivos para la preparación de agentes de contraste de ultrasonido.
AU359486S (en) Medical tray